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Introduction: Body contouring injections by non-licensed providers are frequently sought out by a subset of the
male-to-female transgender community. Although short-term side effects such as pulmonary embolism and
injection site infection are well known, long-term consequences of such practices are less well studied.
Case presentation: Here we describe the case of a 40-year-old African American male-to-female transgender
patient who presented to our institution with hypercalcemia and acute renal failure secondary to body contouring
injections with industrial strength silicone by non-licensed providers, a decade prior to her visit. Work-up revealed
an extensive granulomatous inflammatory process in the injection area resulting in electrolyte abnormalities and
kidney injury. The patient’s lab results and symptoms responded well to long-term corticosteroid treatment and
correlated with treatment adherence.
Conclusion: Affected patients can sometimes present with unusual clinical symptoms many years after silicone
injections. In a constantly growing transgender community that often utilizes non-licensed providers for silicone
injections, the medical community will likely face an increasing number of patients with long-term side effects of
such practices. Therefore, it is imperative for physicians to recognize such cases promptly and initiate potentially
life-saving treatment.
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Injections with various fillers, including mineral and or-
ganic oils like paraffin, petrolatum, camphor oil, silicone
and vegetable oils have been practiced for more than a cen-
tury. The first known injection in modern medical history
was performed by an Austrian surgeon, Robert Gersuny in
1899 [1,2]. He injected Vaseline®, a petroleum jelly brand,
into the scrotal sack of a patient who underwent orchiec-
tomy due to tuberculous epididymitis. His peer, Eckstein
established the use of paraffin as an alternative to petrol-
eum jelly, since it had a higher melting temperature (65°C)
and therefore did not soften after the injection. Paraffin was
injected in a semi-liquid state after heating, and solidified
as it got colder, remaining stable and inert in the human
body [1]. Soon other indications followed with both* Correspondence: koppanyvisnyei@gmail.com
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reproduction in any medium, provided the orVaseline® and paraffin, which were used to treat various
medical conditions including fistulae, nasal defects and
micrognathia, but were also used for wrinkles and body
part augmentation, mostly in the breasts and the penis [1].
Such injections remained popular for the first few decades
of the 20th century, until long-term side effects became
evident in the form of paraffinomas and lipogranulomas.
These tumors developed through the dissemination of the
foreign material and were extremely difficult to treat [3,4].
Today, an entire century later, we are witnessing a renais-
sance of body filler injections, albeit with much improved
techniques and most importantly, refined, high-tech mate-
rials. While such materials seem to enable a relatively safe
and side effect poor application, a large number of patients
use cheap and unpurified industry-grade products, seem-
ingly due to their financial and accessibility benefits.
Additionally, these fillers are often administered by non-
licensed providers, exposing patients to further risk of
developing health problems. This is a growing problemLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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where body-contouring is a much sought-after part of body
image transformation.
While immediate and short-term complications of such
practices are well known and can be diagnosed relatively
easily, much less is known about long-term complications,
which are also more challenging to recognize [3,5,6]. The
major problem is still the development of foreign body
granulomatous reactions, and various associated medical
conditions. Here we present a case of a transgender patient
who presented to our institution with unusual and remark-
ably serious long-term complications of hypercalcemia and
kidney failure after industry-grade silicone injections for
body contouring purposes.
Case presentation
A 40-year-old African American male-to-female trans-
gender patient presented with malaise, dysuria, abdominal
pain, increased thirst and blurred vision. The patient’s med-
ical history included human immunodeficiency virus (HIV)
infection and extensive body contouring injections with
industry-grade silicone a decade prior. On physical exam,
the patient exhibited massive, hardened, painful and some-
what erythematous bilateral subcutaneous deposits in the
gluteal and thigh area (Figure 1). Laboratory studies re-
vealed hypercalcemia (12.3mg/dl, norm: 8.8-10.3mg/dl) and
acute kidney injury with elevated creatinine (1.56mg/dl, pa-
tient’s baseline 0.70mg/dl, norm: 0.6-1.2mg/dl). The patient
had a viral load of <75 copies/ml and a CD4 count of 361
cells/mm3 while on Isentress® and Combivir® antiretroviral
regimen. She had normal 1,25 dihydroxy-vitamin D
(calcitriol) level (47pg/ml; norm: 15-75pg/ml), decreased
25-hydroxyvitamin D (calcidiol) level (16ng/ml; norm:Figure 1 Physical exam findings in the area of silicone injections. The
deposits in the bilateral gluteal and thigh area, one decade after extensive30-80 ng/ml) and decreased parathyroid hormone (PTH)
<2.0pg/ml (norm: 10-60pg/ml).
The patient underwent gallium-67 uptake scan that
showed diffuse tracer uptake in the perigluteal soft tissue
corresponding to the subcutaneous densities on physical
exam. Computed tomography (CT) images showed large
amounts of diffusely infiltrating granulomatous tissue
(Figure 2). Groin lymph node biopsy showed benign
reactive changes with histiocytes, lipid-containing vacu-
oles, inflammatory cells and occasional multinucleated
giant cells, consistent with lipogranuloma (Figure 3).
The patient’s remaining work-up including chest x-ray,
chest CT, anti-nuclear antibody and TSH levels, Quanti-
FERON®-TB Gold In-Tube Test and fecal ova and para-
site test revealed no abnormalities.
Based on the physical, laboratory, imaging and histo-
logical findings, the diagnosis of hypercalcemia caused by
silicone-induced granulomatous disease was established. In
this condition, PTH is typically suppressed by high calcium
levels and hypercalcemia occurs due to PTH-independent
extrarenal production of 1,25 dihydroxy-vitamin D from
25-hydroxyvitamin D by activated mononuclear cells [7].
In our patient, additional causes of hypercalcemia, like
hyperparathyroidism, myeloma, bony metastases, paraneo-
plastic syndrome, milk-alkali syndrome, sarcoidosis, tuber-
culosis, strongyloidiasis or excessive use of vitamin D were
ruled out, with laboratory tests and imaging studies as
described above. Additionally, the patient did not admit to
exogenous vitamin A or estrogen administration and was
on continuous antiretroviral therapy without the possibility
of immune reconstitution syndrome, which could have all
resulted in, or contributed to hypercalcemia [8]. The patient




Figure 2 Imaging data showing extensive grannulomatous disease in the hip region. A - Axial computed tomography (CT) images
showing large amounts of diffusely infiltrating granulomatous tissue (arrows). B - Gallium-67 uptake scan showing diffuse tracer uptake in the
perigluteal soft tissue, corresponding to the subcutaneous densities on physical exam. Images were taken before (i) and after (ii) initiation of
systemic corticosteroid therapy, improving the patient’s condition over time.
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calcium level and kidney function normalized, and nuclear
imaging showed a decreased level of inflammation
(Figure 2B). Non-compliance with treatment resulted in
increasing calcium levels (up to 18.0mg/dl), demonstrating
the importance of the long-term use of corticosteroids. Of
note, due to the excessive and diffusely infiltrating nature of
her disease, the patient was deemed not to be a surgical
candidate (Figure 4).Figure 3 Groin lymph node biopsy showing benign reactive
changes consistent with lipogranuloma. Note the histiocytes,
lipid-containing vacuoles, inflammatory cells and occasional
multinucleated giant cells (inset).Discussion
Injection of organic or inorganic oils has been described
to lead to development of a foreign body reaction in the
form of a chronic granulomatous inflammation. This
happens after an acute inflammatory phase of several
months followed by a latent phase that can last several
years [9]. The average time to development of first clin-
ical symptoms including sclerodermatous skin changes,
tissue hardening, skin hyperpigmentation and development
of subcutaneous lumps, nodules and occasional ulcerations,
is approximately 6 years [10]. The tumors caused by
granulomatous reaction are called oleomas, paraffinomas
or siliconomas, depending on the foreign material involved.
Many foreign-body induced tumors have been de-
scribed in the literature, however the major cause of
presentation is almost always of cosmetic nature [4,6].
Our case stands out due to the unusually serious presen-
tation with clinically symptomatic hypercalcemia and
renal failure. While the development of calcitriol-related
hypercalcemia in granulomatous diseases in general has
been well described, it has not been associated with body
contouring-induced siliconomas. A potential possibility
for the severe electrolyte changes in this particular case
might be the unusually large amount of injected material
and the large anatomic area involved.
Conversion of inactive vitamin D to its active form










Figure 4 Corrected serum calcium levels over time. Note the gradually increasing calcium levels before treatment and the drop of calcium
concentrations during therapy. Non-compliance with treatment resulted in repeatedly increasing calcium levels, demonstrating the importance of














Figure 5 Production of active vitamin D in renal and immune
cells. Vitamin D3 is initially 25-hydroxylated to the main circulating
form of vitamin D, 25-hydroxy vitamin D. This molecule is then
1alpha-hydroxylated to the active form of vitamin D, 1,25-dihydroxy
vitamin D. This binds to the vitamin D receptor (VDR) in the nucleus
and forms heterodimers with the retinoid X receptor (RXR). The
complex acts as a transregulatory complex, controlling transcription
of several genes. The enzyme 24-hydroxylase acts as a negative
feedback control pathway by synthesizing inactive 1, 24,
25-trihydroxy-vitamin D.
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in renal tubular cells, but can also be found at multiple
extrarenal sites, including in immune cells involved in
granulomatous diseases, like the alveolar macrophages
of patients with sarcoidosis [11,12]. The production of
1,25 dihydroxy-vitamin D is regulated by the inhibition
of 1-alpha-hydroxylase activity in response to increased
1,25 dihydroxy-vitamin D levels, and by the intracellular
inactivating enzyme 24-hydroxylase. Interestingly, while
these inhibiting mechanisms are well established in renal
tubular cells, they are much more limited in dendritic
cells and macrophages (Figure 5). These latter ones ex-
hibit very little inhibition of 1-alpha-hydroxylase activity,
and also have a low concentration of 24-hydroxylase,
suggesting a lack of a negative feed-back loop mechan-
ism, resulting in the production of large amounts of 1,25
dihydroxy-vitamin D [13]. It has also been shown that in
inflammatory cells, 1,25 dihydroxy-vitamin D production
is enhanced by γ-interferon, which is produced by acti-
vated lymphocytes and alveolar macrophages in active
sarcoidosis [14]. On the other hand, 1,25 dihydroxy-
vitamin D has been shown to inhibit activated T helper
cells and γ-interferon production. This suggests that the
production of 1,25 dihydroxy-vitamin D by macrophages
might represent a compensatory mechanism to inhibit
the inflammatory process at the site of disease, by limi-
ting T helper cell proliferation and lymphokine produc-
tion [15]. Regardless of the modulatory effect of 1,25
dihydroxy-vitamin D on inflammatory processes, it is
evident that granulomas provide a non-renal source of
1,25 dihydroxy-vitamin D. This has been shown in sar-
coid lymph nodes as well as mononuclear cells isolated
from tuberculosis patients [16,17], but also in mineral-
oil induced paraffinomas, where immunohistochemical
studies showed increased 1-alpha-hydroxylase activity in
macrophages within of the granulomatous tissue [6].
Elevated 1,25 dihydroxy-vitamin D levels lead to in-
creased intestinal absorption and increased bone resorption
of calcium, resulting in hypercalcemia, hypercalcuria,
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parathyroid hormone levels. Hypercalcemia is typically
worsened by renal insufficiency. It usually varies with
calcium intake and can be corrected with dietary
restriction of calcium. Exposure to sunlight might also
worsen hypercalcemia and can cause seasonal variation
of calcium levels [15].
Of note, our patient had normal 1,25 dihydroxy-
vitamin D levels upon presentation. One possible
explanation for this is the low amount of 25 hydroxy-
vitamin D that is available for hydroxylation by 1-alpha-
hydroxylase. This would result in lower than expected
1,25 vitamin D levels, even in the presence of increased
enzyme activity. Therefore, the relative ratio of 25 hy-
droxy and 1,25 dihydroxy vitamin D might be more
informative than the absolute 1,25 dihydroxy vitamin D
level in assessing enzymatic activity in this setting.
Depending on the anatomic location and the extension
of the disease, surgical resection can be often performed,
either with curative or non-curative, debulking intent. In
the case of our patient, surgery was not an option, due
to the bare extent of the disease and due to widespread
tissue infiltration. Furthermore, the patient declined a
figure-altering surgical procedure.
An important observation was that the synthesis of 1,25
dihydroxy-vitamin D in isolated alveolar macrophages of
sarcoma patients markedly diminished by the addition of
dexamethasone, in a dose-dependent manner [14]. This
explains the response of hypercalcemia to steroid treatment
in patients with sarcoidosis and other granulomatous
diseases. Analogously, foreign material-induced granulomas
can be treated conservatively with regionalized corticoster-
oid injections, especially in the case of smaller lesions. Min-
ocycline, cyclosporine and allopurinol have been used with
some success as well [18]. Of note, hydroxychloroquine
and ketoconazole have been shown to be effective in treat-
ing hypercalcemia in sarcoidosis [19,20]. In contrast to
long-term steroids, their milder side effect profiles might
make them preferable candidates, however their exact role
in treating siliconomas and paraffinomas is still to be
explored. In our patient’s case, due to extensive disease,
systemic corticosteroid treatment was necessary along with
specific calcium lowering management. For the latter, treat-
ment options include reducing calcium intake, elimination
of dietary vitamin D supplements, avoidance of sun expos-
ure and if needed, bisphosphonates.
In our case, longitudinally measured calcium levels
seemed to have correlated well with corticosteroid treat-
ment and disease activity, as seen on imaging studies.
Therefore, it might be a useful tool to monitor disease
improvement or progression in patients presenting with
extensive disease and severe hypercalcemia.
Renal failure has been extensively described in
granulomatous diseases, like sarcoidosis. The mainpathophysiological mechanism of kidney involvement
seems to be a granulomatous inflammation confined to the
tubulointerstitial compartment [21], however interstitial
and membranous nephritis without any evidence of
granuloma has been described as well [22]. The exact
mechanism of development of renal failure in siliconoma
or paraffinomas-associated granulomatous disease is still
unclear however.
Conclusion
With a worldwide trend of increasing demand to undergo
physique-altering procedures, in the transgender but also
other communities, we can expect to see more patients
with short and long-term complications of body contouring
practices. Long-term complications include localized skin
changes and the development of lipogranuloma. However,
in case of more extensive disease, hypercalcemia can de-
velop with potentially life-threatening complications. It will
be important to recognize these symptoms as possible
complications of foreign body injections, and to initiate
treatment in a timely manner. Most importantly however,
this report would like to stress the importance of informing
patients about potential side effects of improper and large-
scale body contouring practices by non-licensed providers.
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